Arcus Biosciences, Inc. (RCUS)
| Market Cap | 2.55B |
| Revenue (ttm) | 247.00M |
| Net Income (ttm) | -353.00M |
| Shares Out | 125.35M |
| EPS (ttm) | -3.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,912,457 |
| Open | 19.50 |
| Previous Close | 19.54 |
| Day's Range | 19.50 - 20.44 |
| 52-Week Range | 6.50 - 26.40 |
| Beta | 0.84 |
| Analysts | Buy |
| Price Target | 28.22 (+38.54%) |
| Earnings Date | Feb 25, 2026 |
About RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2α inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical tria... [Read more]
Financial Performance
In 2025, Arcus Biosciences's revenue was $247.00 million, a decrease of -4.26% compared to the previous year's $258.00 million. Losses were -$353.00 million, 24.7% more than in 2024.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for RCUS stock is "Buy." The 12-month stock price target is $28.22, which is an increase of 38.54% from the latest price.
News
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient...
Arcus Biosciences, Inc. (RCUS) Q4 2025 Earnings Call Transcript
Arcus Biosciences, Inc. (RCUS) Q4 2025 Earnings Call Transcript
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...
Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and in...
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient...
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...
Arcus Biosciences, Inc. (RCUS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Arcus Biosciences, Inc. (RCUS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and in...
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient...
Arcus Biosciences: Casdatifan Takes Center Stage After STAR-221
RCUS is now resetting its strategy after its Phase 3 STAR-221 was discontinued. This removes domvanalimab for upper-GI cancers as a key catalyst. Instead, they'll focus now on Casdatifan (AB521), whic...
Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug
Arcus Biosciences, Inc. (NYSE:RCUS) on Friday announced the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead Sciences, Inc. (NASDAQ: GILD), due to futility.
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...
Arcus Biosciences, Inc. (RCUS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Arcus Biosciences, Inc. (RCUS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
TOKYO & HAYWARD, Calif.--(BUSINESS WIRE)--Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Arcus Biosciences, Inc. (NYSE:RCUS, “Arcus”) announced that Taiho exercised its option to develop and, if approve...
Arcus Biosciences: Refusing To Let The TIGIT Story Die, And Finding Potential Niches In Huge Markets
Arcus Biosciences (RCUS) boasts a diverse, promising pipeline with key candidates like domvanalimab, casdatifan, and quemliclustat advancing in pivotal trials. Recent data from RCUS's EDGE-Gastric tri...
Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...
Arcus Biosciences, Inc. (RCUS) Shareholder/Analyst Call Transcript
Arcus Biosciences, Inc. (NYSE:RCUS) Shareholder/Analyst Call October 6, 2025 10:00 AM EDT Company Participants Pia Eaves - Vice President of Investor Relations & Strategy Terry Rosen - Co-Founder, Ch...
Why Is Arcus Biosciences Stock Trading Higher On Monday?
In the relentless quest for groundbreaking cancer therapies, innovative drug trials are reshaping treatment landscapes and redefining patient hope. Arcus Biosciences Inc. (NYSE:RCUS) on Monday announc...
Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...
Arcus Biosciences, Inc. (RCUS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Arcus Biosciences, Inc. (NYSE:RCUS) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 8:30 AM EDT Company Participants Jennifer Jarrett - Chief Operating Officer Richard Mark...
Arcus Biosciences, Inc. (RCUS) Presents At Citi's Biopharma Back To School Conference Transcript
Arcus Biosciences, Inc. (NYSE:RCUS) Citi's Biopharma Back to School Conference September 3, 2025 11:15 AM EDT Company Participants Terry Rosen - Co-Founder, Chairman & CEO Jennifer Jarrett - Chief Op...
Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS) announced today that it will host an in-person and virtual Investor Event for analysts and investors on Monday, October 6, 2025, beginni...